Instructions for Credit - There is no fee for this activity. To receive credit for this CE activity, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for 1.5 continuing education credits. Please retain a copy of the certificate for your records.
Nurses, social workers and other healthcare professionals involved in the care of patients with hematologic malignancies. Course content level for social workers: beginner and intermediate
At the conclusion of this program, participants will be able to:
- Describe the different blood cancers
- Describe the psychosocial impact of different blood cancer diagnoses
- Explain the role of the social worker and nurse as members of the healthcare team
- Educate patients about clinical trial participation
- List resources for patients with blood cancers and how to access them
Laura Romundstad, CRNP, MSN, RN
Clinical Trial Nurse Navigator
Clinical Trial Support Center
The Leukemia & Lymphoma Society
Rye Brook, NY
Lynn Steele, LSW, OSW-C Information Specialist Information Resource Center
The Leukemia & Lymphoma Society Rye Brook, NY
Continuing Education Information:
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.5 continuing education contact hour through the California Board of Registered Nursing.
Social Work Credit Designation
The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education (ACE) program. Organizations not individual courses are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/2020 to 12/10/2023. Social workers completing this course receive 1.5 continuing education credit.
LLS is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.
All continuing education credits are provided free of charge.
Disclosure of Conflicts of Interest:
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by The Leukemia & Lymphoma Society for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity during the past 12 months.
Laura Romundstad, CRNP, MSN, RN has no affiliations to disclose.
Lynn Steele, LSW, OSW-C has no affiliations to disclose.
Disclaimer - The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Provider: The Leukemia & Lymphoma Society
Estimated time to complete activity: 1.5 hours
Date of initial release: March 30, 2021
Valid for CE credit through: September 30, 2022
For questions, concerns, or for assistance for people with disabilities or grievances, please contact ProfEducation@LLS.org